Mallinckrodt Recognizes First Hepatorenal Syndrome (HRS) Awareness Day

– HRS Awareness Day will be observed annually on October 14 during National Liver Awareness Month, with the goal of raising awareness around a life-threatening condition that occurs in people with advanced liver disease¹–

DUBLIN, Oct. 14, 2025 /PRNewswire/ -- Mallinckrodt plc, a global specialty pharmaceutical company, today announced that the Company supports the inaugural Hepatorenal Syndrome (HRS) Awareness Day, established by the American Liver Foundation (ALF). HRS Awareness Day will be observed on October 14 during National Liver Awareness Month. The purpose of this initiative is to promote increased awareness and education regarding HRS, including potential complications, the importance of early detection and treatment, and to honor the stories of HRS patients and their experiences.

HRS is classified into two distinct types – a rapidly progressive type that leads to renal failure where patients are typically hospitalized for their care (HRS-acute kidney injury (AKI)) and a more chronic type that progresses slowly over weeks to months (HRS-chronic kidney disease (CKD)).^1,2 HRS is estimated to affect more than 60,000 Americans annually, approximately 0.01% of the U.S. population,³ making it a rare condition; and rates of HRS hospitalizations are increasing.⁴

"We're proud to support this moment for the HRS community and help to raise visibility of this condition and the patients, care teams, and healthcare professionals it impacts," said Dr. Marek Honczarenko, Executive Vice President and Chief Scientific Officer, Mallinckrodt. "U.S. physicians historically have faced significant challenges treating patients with HRS."

"HRS is a life-threatening complication of liver disease,¹ so it is fitting to elevate knowledge about this condition and recognize those affected by it during National Liver Awareness Month," said Lorraine Stiehl, CEO, American Liver Foundation. "Thank you to our sponsors, including Mallinckrodt, who have made this awareness day possible and are committed to bringing treatment options to patients in need."

ABOUT MALLINCKRODT
Mallinckrodt is dedicated to enhancing lives by providing therapeutics that strive to address unmet patient needs, and is a world-class manufacturer of high-quality generics, sterile injectables, and active pharmaceutical ingredients.

Our company consists of multiple wholly owned subsidiaries that operate in two businesses. Our Brands business is focused on autoimmune and rare diseases in areas including endocrinology, gastroenterology, hepatology, neonatal respiratory critical care, nephrology, neurology, pulmonology, ophthalmology, orthopedics, rheumatology, and urology. Our Par Health business includes generic drugs, sterile injectables, and active pharmaceutical ingredients. To learn more, visit www.MNK-Endo.com.

CONTACT

Media Inquiries
Green Room Communications
908-577-4531
[email protected]

Investor Relations
Juan Avendano
862-240-8194
[email protected]

Patient Advocacy
Derek Naten
202-257-5904
[email protected]

Mallinckrodt, the "M" brand mark and the Mallinckrodt Pharmaceuticals logo are trademarks of a Mallinckrodt company. Other brands are trademarks of a Mallinckrodt company or their respective owners.

©2025 Mallinckrodt. US-2500552 10/25

References

¹ National Organization for Rare Disorders. Hepatorenal Syndrome. Available at: https://rarediseases.org/rare-diseases/hepatorenal-syndrome/. Accessed October 2025.
² Flamm S.L., Brown K., Wadei H.M., et al. The Current Management of Hepatorenal Syndrome–Acute Kidney Injury in the United States and the Potential of Terlipressin. Liver Transpl. 2021;27:1191-1202. https://doi.org/10.1002/lt.26072.
³ United States Census Bureau: Quick Facts. Available at: https://www.census.gov/quickfacts/fact/table/US/PST045218. Accessed October 2025.
⁴ Wong R.J., Balasubramanain J., Panaccio M., et al. Acute Kidney Injury and Hepatorenal Syndrome Among Hospitalized Patients With Chronic Liver Disease. JAMA Netw Open. 2025;8(5):e2511816. doi:10.1001/jamanetworkopen.2025.11816

SOURCE Mallinckrodt plc